

---

<b>Product name:</b>	LATS1 Rabbit Monoclonal Antibody
<b>Cat number:</b>	MABN21250
<b>Conjugate:</b>	Unconjugated
<b>Size:</b>	100µL
<b>Clone:</b>	Monoclonal
<b>Concentration:</b>	1mg/ml
<b>Host:</b>	Rabbit
<b>Isotype:</b>	IgG,Kappa
<b>Immunogen:</b>	Recombinant protein of human LATS1/WARTS
<b>Reactivity:</b>	Human,Mouse,Rat,
<b>Applications:</b>	WB 1:2000-1:10000,ICC/IF 1:200-1:1000,ELISA 1:5000-1:20000,IP 1:50-1:200
<b>Molecular Weight:</b>	Calculated MW:127kD;Observed MW:140kD
<b>Purification:</b>	Protein A
<b>Form:</b>	Liquid
<b>Buffer:</b>	PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
<b>Storage:</b>	Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles.
<b>Background:</b>	<p>Cell localization:Cytoplasm.The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatment</p>